FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

A Fandi

Research Profile

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Karim Fizazi; H Doubre; Thierry Le Chevalier; A Riviere; Juliette Viala; C Daniel; L Robert; P Barthélemy; A Fandi; Pierre Ruffié
Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
Karim Fizazi; Raffaele Caliandro; Patrick Soulié; A Fandi; C Daniel; A Bedin; H Doubre; Juliette Viala; Jean-François Rodier; L Trandafir; Thierry Le Chevalier; Esteban Cvitkovic; Jean-Pierre Armand; Pierre Ruffié
Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma.
Karim Fizazi; Michel Ducreux; Pierre Ruffié; Marc Bonnay; C Daniel; J C Soria; C Hill; A Fandi; M Poterre; M Smith; Jean-Pierre Armand
Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of A Fandi (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2003: Karim Fizazi; H Doubre; Thierry Le Chevalier; A Riviere; Juliette Viala; C Daniel; L Robert; P Barthélemy; A Fandi; Pierre Ruffié
Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):349-54.
2000: Karim Fizazi; Raffaele Caliandro; Patrick Soulié; A Fandi; C Daniel; A Bedin; H Doubre; Juliette Viala; Jean-François Rodier; L Trandafir; Thierry Le Chevalier; Esteban Cvitkovic; Jean-Pierre Armand; Pierre Ruffié
Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma.
European journal of cancer (Oxford, England : 1990) 2000;36(12):1514-21.
2000: Karim Fizazi; Michel Ducreux; Pierre Ruffié; Marc Bonnay; C Daniel; J C Soria; C Hill; A Fandi; M Poterre; M Smith; Jean-Pierre Armand
Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(11):2293-300.
2000: A Fandi; M Bachouchi; Nacer Azli; Abdelkrim Taamma; H Boussen; Pierre Wibault; François Eschwege; Jean-Pierre Armand; J Simon; Esteban Cvitkovic
Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(6):1324-30.
1999: Abdelkrim Taamma; A Fandi; Nacer Azli; Pierre Wibault; N Chouaki; Ali Hasbini; Corinne Couteau; Jean-Pierre Armand; Esteban Cvitkovic
Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type.
Cancer 1999;86(7):1101-8.
1999: Ali Hasbini; R Mahjoubi; A Fandi; N Chouaki; Abdelkrim Taamma; P Lianes; H Cortès-Funes; S Alonso; Jean-Pierre Armand; Esteban Cvitkovic; Eric Raymond
Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(4):421-5.
1998: Michel Ducreux; Philippe Rougier; A Fandi; Marie-Christine Clavero-Fabri; A L Villing; F Fassone; L Fandi; J Zarba; Jean-Pierre Armand
Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(6):653-6.
1997: A Fandi; Abdelkrim Taamma; Nacer Azli; M Bachouchi; B Yanes; Jean-Pierre Armand; Esteban Cvitkovic
Palliative treatment with low-dose continuous infusion 5-fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma type.
Head & neck 1997;19(1):41-7.
1995: Nacer Azli; A Fandi; M Bachouchi; mohamed rahal; P Lianes; Pierre Wibault; H Boussen; François Eschwege; Jean-Pierre Armand; Esteban Cvitkovic
Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type.
The cancer journal from Scientific American 1995;1(3):222-9.
1995: Musa Altun; A Fandi; O Dupuis; E Cvitkovic; Z Krajina; François Eschwege
Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects.
International journal of radiation oncology, biology, physics 1995;32(3):859-77.
1995: A Fandi; Esteban Cvitkovic
Biology and treatment of nasopharyngeal cancer.
Current opinion in oncology 1995;7(3):255-63.
1994: A Fandi; B Yanes; Abdelkrim Taamma; Nacer Azli; Jean-Pierre Armand; O Dupuis; François Eschwège; Guy Schwaab; Esteban Cvitkovic
[Undifferentiated carcinoma of the nasopharynx: epidemiological, clinical and therapeutic aspects].
Bulletin du cancer 1994;81(7):571-86.
1994: A Fandi; Musa Altun; Nacer Azli; Jean-Pierre Armand; Esteban Cvitkovic
Nasopharyngeal cancer: epidemiology, staging, and treatment.
Seminars in oncology 1994;21(3):382-97.